Icecure Medical Ltd. (ICCM) has released an update.
IceCure Medical Ltd. reported a robust 26% increase in global sales of its ProSense cryoablation systems and disposables in 2023, signaling a successful shift toward commercialization. The company is poised to submit its ICE3 breast cancer study data to the FDA, potentially enhancing ProSense’s market demand upon clearance. This momentum is underscored by a strong portfolio of independent studies and new regulatory approvals, supporting broader adoption and potential new indications for the ProSense technology.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.